Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers
This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
First received: October 4, 2005
Last updated: April 25, 2012
Last verified: April 2012
This study will assess the safety and efficacy of co-artemether in the treatment of acute uncomplicated P. falciparum malaria in returning non-immune travellers
THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
Acute Uncomplicated P. Falciparum Malaria
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Open-label, Multi-center, Non-comparative Efficacy, Safety, and Tolerability Study of Co-artemether in the Treatment of Acute Uncomplicated Malaria in Non-immune Patients
Primary Outcome Measures:
- Proportion of patients free of parasites in the blood after 28 days.
Secondary Outcome Measures:
- Proportion of patients free of parasites in the blood after 7 days
- Time to clearance of fever
- Time to clearance of parasites in the blood
- Proportion of patients with presence of sexual forms of the parasite in the blood (gametocytes);
- Hematology and biochemistry
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||August 2005 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
Patients were eligible for inclusion if they met all of the following criteria:
- Male or female aged 18 or older (prior to Amendment 1: more than 2 years old)
- Non-immune patients suffering from acute uncomplicated P. falciparum malaria, or mixed infection including P. falciparum, with parasitemia of less than or equal to 2% asexual P.falciparum parasites, confirmed by microscopy using Giemsa-stained thick film.
- Non-immune patients were regarded as those who had not spent the first five years of their life, nor the last five years in a malaria endemic area, and did not have acute P. falciparum malaria diagnosed during those past five years.
- Non-immune patients who had received prophylaxis with anti-malarials (excluding halofantrine) were included only if clear progression of acute P. falciparum infection was documented.
- Female patients were eligible to participate in the study if they were of non-childbearing potential or had a negative pregnancy test (urine or serum) at screening, and using an acceptable contraceptive method
- Patients, who had been informed of the study procedures and medication, and had given written informed consent and were willing to comply with the study protocol.
Other protocol inclusion/exclusion criteria may apply
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00233337
No publications provided
||Novartis ( Novartis Pharmaceuticals )
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 4, 2005
||April 25, 2012
Germany: Federal Institute for Drugs and Medical Devices
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Italy: The Italian Medicines Agency
Netherlands: Medicines Evaluation Board (MEB)
Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Keywords provided by Novartis:
Malaria, non-immune travelers
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 26, 2015